CRISPR Therapeutics AG (CRSP) Stock Price & Analysis
CRISPR Therapeutics AG (CRSP) closed at USD 54.26 on Thursday, October 29, 2026, up 0.28% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 54.11; the Oct 29, 2026 session ranged USD 53.3–55.82 on volume of 1,290,824 shares. Market capitalization is $5.25B, with a 52-week range of USD 44.12–65.98 (NGM). Source: Nexqual, retrieved October 29, 2026 at 21:58 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CRSP.md
Key facts (CRSP)
- Last four reported quarters (through Jun 30, 2026): revenue $13.4M, net income -$451M (-3368.7% margin), free cash flow -$371M (SEC filings).
- Insider open-market sales, last ~7 months: 8 Form 4 filings, $5.1M; 5 not under a Rule 10b5-1 plan ($3.6M); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.26 on a 1–5 scale) (23 analysts), mean target USD 85.63 (range 44–291).
- Total return with dividends: 1Y -11.2% vs S&P 500 +14.4%; 5Y -40.6% vs S&P 500 +79.1%.
- Next earnings: 2026-11-09 (date not yet confirmed by the company), EPS estimate USD -1.06, revenue estimate $16.6M. All companies reporting that day: https://nexqual.com/earnings/2026-11-09
- Dividend: CRSP paid no cash dividend in the last five years.
- Short interest: 19.47% of float (as of 2026-10-15), 9.2 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CRSP)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $915M | $1.2M | $371M | $37.3M | $3.5M | $13.4M |
| Operating income | $374M | -$673M | -$223M | -$467M | -$665M | -$534M |
| Net income | $378M | -$650M | -$154M | -$366M | -$582M | -$451M |
| EPS (diluted) | $4.70 | -$8.36 | -$1.94 | -$4.34 | -$6.47 | — |
| Free cash flow | $457M | -$533M | -$270M | -$145M | -$346M | -$371M |
| Operating margin | 40.8% | -56190.4% | -60.0% | -1250.4% | -18933.6% | -3990.0% |
| Net margin | 41.3% | -54271.7% | -41.4% | -981.5% | -16569.8% | -3368.7% |
| Revenue growth | +127154.9% | -99.9% | +30885.5% | -89.9% | -90.6% | — |
| Cash + short-term investments | $2.38B | $1.82B | $1.69B | $1.90B | $1.98B | — |
| Total debt | — | — | — | — | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CRSP)
P/S 391.8x · EV/Sales 259.0x · P/B 3.0x · FCF yield -7.08% · Earnings yield -8.60% · Net cash $1.78B · EV $3.47B
Insider sales (SEC Form 4, open-market, last ~7 months) (CRSP)
3 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Kulkarni Samarth | Chief Executive Officer | 47,837 | $2.4M | 13.3% | No | Routine (sold in Feb & Mar each year 2023–2025; this trade is outside those months) |
| 2026-10-14 | George Simeon | Director | 14,514 | $720K | 0.7% | Yes (adopted December 12, 2025) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-10-14 | Kasinger James R. | General Counsel and Secretary | 1,040 | $51K | 1.1% | No | Too little history (no open-market trades in 2023) |
| 2026-10-14 | Kulkarni Samarth | Chief Executive Officer | 4,098 | $202K | 1.6% | No | Routine (sold in Feb & Mar each year 2023–2025; this trade is outside those months) |
| 2026-10-06 | Kasinger James R. | General Counsel and Secretary | 1,990 | $119K | 2.1% | Yes (adopted May 6, 2026) | Too little history (no open-market trades in 2023) |
| 2026-09-22 | Kasinger James R. | General Counsel and Secretary | 10,400 | $626K | 9.9% | Yes (adopted May 6, 2026) | Too little history (no open-market trades in 2023) |
| 2026-09-17 | Behbahani Ali | Director | 13,679 | $781K | 45.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-29 | Patel Naimish | Chief Medical Officer | 3,786 | $211K | 16.4% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CRSP)
Consensus Buy (mean 2.26 on a 1–5 scale), 23 analysts; mean target USD 85.63 (low 44, high 291).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | UBS | Initiated | Neutral | $52 |
| 2026-08-31 | Citizens | Reiterated | Market Outperform | $80 |
| 2026-08-31 | Needham | Reiterated | Buy | $82 |
| 2026-08-25 | Citizens | Reiterated | Market Outperform | $80 |
| 2026-08-04 | Citigroup | Target raised | Buy | $82 → $88 |
| 2026-07-08 | HC Wainwright & Co. | Reiterated | Buy | $80 |
| 2026-07-06 | Citizens | Reiterated | Market Outperform | $80 |
Total return (dividends reinvested) (CRSP)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -11.2% | -40.6% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | -11.2% | -9.9% |
| Volatility (annualized) | 57.4% | 55.5% |
| Max drawdown | -30.7% (Oct 2025→Mar 2026) | -64.3% (Oct 2021→Mar 2025) |
Dividends (CRSP)
CRSP paid no cash dividend in the last five years.
Short interest (CRSP)
16,442,415 shares sold short, 19.47% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 19,071,093 shares (-13.8%). Days to cover: 9.2 (short shares ÷ average daily volume).
CRSP earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 3, 2026 | Quarter ended Jun 30, 2026 | −$0.94 | −$1.18 | Beat +20.3% | +10.6% |
| May 4, 2026 | Quarter ended Mar 31, 2026 | −$1.28 | −$1.23 | Miss −4.1% | +1.5% |
| Feb 12, 2026 | Quarter ended Dec 31, 2025 | −$1.37 | −$1.23 | Miss −11.4% | +9.8% |
| Nov 10, 2025 | Quarter ended Sep 30, 2025 | −$1.17 | −$1.29 | Beat +9.3% | +0.2% |
| Aug 4, 2025 | — | — | — | — | -0.9% |
| May 6, 2025 | — | — | — | — | -9.0% |
| Feb 11, 2025 | — | — | — | — | +9.9% |
| Nov 5, 2024 | — | — | — | — | +0.3% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CRSP recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 19, 2026 | 8-K | Director or executive officer change, or pay arrangement “a) Appointment of New Chief Financial Officer Appointment of Andrew J. Silver as Chief Financial Officer On October 19, 2026, CRISPR Therapeutics AG (the "Company") announced the promotion of Andrew J. Silver, currently the Company's SVP, Finance, to be the Company's Chief Financial Officer effective immediately. Mr. Silver will also serve as the Company's principal financial officer and principal accounting officer. Since January 2025, Mr. Silver, aged 42, has served as the Company's Senior Vice President of…” |
| Aug 14, 2026 | Schedule 13G/A | ORBIS INVESTMENT MANAGEMENT LTD, Allan Gray Australia Pty Ltd: 5.6% of shares, passive 5%+ holder (amended) |
| Aug 3, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 3, 2026 | 8-K | Quarterly results |
| Jul 27, 2026 | Schedule 13G/A | BlackRock, Inc.: 8.3% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
CRSP revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Collaboration Revenue | $10.0M | 98.2% | — |
| Grant | $181,000 | 1.8% | -79.7% |
| Total revenue | $10.2M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CRSP suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Eli Lilly (LLY) | “We have also established a collaboration and clinical supply agreement with Eli Lilly to evaluate zugo-cel together with pirtobrutinib in aggressive B-cell lymphomas, further expanding the program's development in oncology.” |
| Partner | Vertex Pharmaceuticals | “We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.” |
| Partner | Jefferies | “For example, we actively maintain a sales agreement with Jefferies under which we are able to offer and sell, from time to time at our sole discretion through Jefferies, as our sales agent, our common shares, par value of CHF 0.03 per share.” |
| Partner | Sirius Therapeutics | “In May 2025, we entered into a Collaboration, Option and License Agreement, or the Sirius Agreement, with Sirius Therapeutics, or Sirius-CY, and Sirius Therapeutics, Inc., or Sirius-US, and together with Sirius-CY, Sirius, pursuant to which, among other things, (1) we and Sirius-US will collaborate on the research, development, manufacture, commercialization and use of certain collaboration products utilizing Siri…” |
| Competitor | Johnson & Johnson (JNJ) | “These competitors are developing ex vivo CAR T therapies, in vivo CAR T therapies, and stem cell-derived cell therapies and include Allogene, Autolus, BlueRock Therapeutics (acquired by Bayer in 2019), Bristol Myers Squibb, Caribou Biosciences, Cellectis, Fate Therapeutics, Iovance Biotherapeutics, Johnson & Johnson, Kite Pharma (acquired by Gilead Sciences in 2017), and Novartis.” |
| Competitor | AbbVie (ABBV) | “Of these companies, those focused on transduction of hematopoietic stem progenitor cells or their progeny (e.g., T-cells, B-cells, NK cells, dendritic cells) pose the greatest competitive threat, including Azalea Therapeutics, Beam Therapeutics, Capstan (recently acquired by AbbVie), Editas Medicine, Ensoma, Interius Biotherapeutics (recently acquired by Kite Pharma / Gilead Sciences), Tessera Therapeutics, Keloni…” |
Quoted from the company's 10-K filed Feb 12, 2026.
Companies that name CRSP in their SEC reports
| Relationship to CRSP | Company | Filing | Sentence |
|---|---|---|---|
| partner | Nkarta, Inc. (NKTX) | 10-K Mar 25, 2026 | “advance additional product candidates to clinical trials, including any product candidates that may be advanced under the collaboration with CRISPR Therapeutics AG ("CRISPR");” |
| partner | Cellectis S.A. (CLLS) | 20-F Mar 20, 2026 | “Autologous and Allogeneic CAR T-cell space: Bristol-Myers Squibb, Gilead Sciences Inc., Novartis AG, Johnson & Johnson, Regeneron Pharmaceuticals Inc., Fate Therapeutics Inc., CRISPR Therapeutics Inc., Caribou Biosciences Inc., Takeda Pharmaceutical Company Limited, Mustang Bio, Atara Biotherapeutics Inc., Adaptimmune (in collaboration with Astellas), Poseida Therapeutics Inc. (acquired by F.” |
| partner | Adicet Bio, Inc. (ACET) | 10-K Mar 12, 2026 | “+ License agreement with CRISPR for gene-editing technology.” |
| partner | Intellia Therapeutics, Inc. (NTLA) | 10-K Feb 26, 2026 | “For example, with respect to our sublicensed rights from Caribou to UC/Vienna/Charpentier intellectual property, UC retained the right to control the prosecution, enforcement and defense of this intellectual property in its license agreement with Caribou and, pursuant to an Invention Management Agreement, shares these responsibilities with CRISPR Therapeutics AG and, under certain circumstances, ERS Genomics, Ltd.…” |
CRSP analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-1.06 | $-1.19 | +$0.13 | $16.6M | 17 |
| Next quarter (ends Dec 2026) | $-1.16 | $-1.23 | +$0.07 | $17.4M | 17 |
| Current fiscal year (ends Dec 2026) | $-4.45 | $-4.88 | +$0.43 | $40.4M | 19 |
| Next fiscal year (ends Dec 2027) | $-3.55 | $-3.89 | +$0.33 | $154.0M | 19 |
CRSP options: expected move
Options price a move of about ±9.8% (±$5.28) by Nov 13, 2026, which includes earnings on Nov 9, 2026; the earnings reaction alone is priced at about ±3.8%. Over the last 8 reports the stock moved ±5.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 1 | 57.7% | ±2.6% |
| Nov 6, 2026 | 8 | 58.8% | ±7.0% |
| Nov 13, 2026 | 15 | 60.2% | ±9.8% |
| Nov 20, 2026 | 22 | 56.2% | ±11.9% |
| Nov 27, 2026 | 29 | 58.6% | ±13.3% |
| Dec 4, 2026 | 36 | 56.0% | ±14.2% |
| Dec 11, 2026 | 43 | 58.0% | ±16.0% |
| Dec 18, 2026 | 50 | 55.3% | ±16.4% |
30-day implied volatility 57.2% vs 48.6% realized over the last 30 trading days. Put/call ratio (volume) 0.3. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 21:58 UTC)
| Price | USD 54.26 |
|---|---|
| Change | ▲ 0.28% (up) |
| Previous Close | USD 54.11 |
| Open | USD 54.3 |
| Day Range | USD 53.3 – 55.82 |
| 52-Week Range | USD 44.12 – 65.98 |
| Volume | 1,290,824 shares |
| Market Cap | $5.25B |
| Exchange | NGM |
Technical Analysis (CRSP)
Nexqual's technical model rates CRSP "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 21:58 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 57.42 (neutral) |
| vs SMA50 | Below (USD 54.32) |
| MACD | -0.6 (negative) |
Analyst Ratings (CRSP)
Wall Street analysts rate CRSP "Buy" based on 23 analysts, with a mean price target of USD 85.63 (range USD 44–291), per Nexqual as of October 29, 2026 at 21:58 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 85.63 |
| High Target | USD 291 |
| Low Target | USD 44 |
| Buy / Hold / Sell | 13 / 10 / 0 |
Earnings (CRSP)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -1.06 |
| Revenue Estimate | $16.56M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.94 vs est -1.18 ▲ beat |
| 2026-03-31 | USD -1.28 vs est -1.23 ▼ miss |
| 2025-12-31 | USD -1.37 vs est -1.23 ▼ miss |
| 2025-09-30 | USD -1.17 vs est -1.29 ▲ beat |
Source: Nexqual, October 29, 2026 at 21:58 UTC.
Financials & Fundamentals (CRSP)
| Total Revenue | $13.39M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1041.40% |
| Gross Margin | +0.00% |
| Operating Margin | -1127.55% |
| Profit Margin | +0.00% |
| ROE | -26.10% |
| Debt / Equity | 0.45 |
| Current Ratio | 17.85 |
| Total Cash | $2.36B |
| Total Debt | $783.75M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$371.32M (-2772.7% of revenue) |
Source: Nexqual, October 29, 2026 at 21:58 UTC.
Financial Health Score (CRSP)
Nexqual rates CRISPR Therapeutics AG's overall financial health "Weak" across five dimensions, as of October 29, 2026 at 21:58 UTC.
| Growth | Critical — Revenue -91% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $2.36B cash and investments vs $586M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$371M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -26%, ROA -17.0% (last 4 quarters, SEC) |
Ownership (CRSP)
| Insider Ownership | +5.97% |
|---|---|
| Institutional Ownership | +78.24% |
| Shares Outstanding | 96.69M |
| Float | 96.18M |
| Short % of Float | +19.47% |
Source: Nexqual, October 29, 2026 at 21:58 UTC.
Leadership (CRSP)
CRISPR Therapeutics AG is led by Samarth Kulkarni, CEO & Chairman, per Nexqual as of October 29, 2026 at 21:58 UTC.
| CEO & Chairman | Samarth Kulkarni |
|---|
Major Backers & Investors (CRSP)
Notable institutional backers of CRISPR Therapeutics AG include ARK Invest, Orbis Allan Gray Ltd, Capital Group, according to Nexqual as of October 29, 2026 at 21:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 9.78% |
| Orbis Allan Gray Ltd | 5.64% |
| Capital Group | 4.91% |
| GSK plc | 3.33% |
| T. Rowe Price | 2.12% |
| SR One Capital Management, LP | 2.11% |
| Two Sigma Investments, LP | 2.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.63% |
| State Street | 4.47% |
| Geode Capital | 2.6% |
Source: Nexqual, October 29, 2026 at 21:58 UTC.
From CRISPR Therapeutics AG's Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, we have developed a proprietary, next-generation, site-specific gene correction platform called SyNTase editing.
- We continue to innovate on our platform to develop next-generation technologies that can enable new therapies.
- We believe that our innovative research, translational expertise, and clinical development experience, position us as a leader in the development of CRISPR-based therapeutics and may enable us to create an entirely new class of highly effective and potentially curative therapies for patients with both common and rare diseases for whom current biopharmaceutical approaches have had limited success.
- Our CRISPR/Cas9 platform enables us to innovate continuously by incorporating incremental edits into next-generation products.
Partnerships
- CASGEVY is the first therapy to emerge from our strategic partnership with Vertex and is being advanced under a joint development and commercialization agreement between us and Vertex and certain of its affiliates.
- In 2015, we partnered with Vertex and entered into a strategic collaboration, option and license agreement, which focused on the discovery and development of gene-based treatments for hemoglobinopathies and cystic fibrosis using CRISPR/Cas9 gene-editing technology.
Legal & Regulatory Risks (Item 1A, quoted)
- Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| KOD | Kodiak Sciences Inc | USD 100.4 | ▲ 3.46% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 21:58 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt